Research map: Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK

Back to the article

Papers in this map

  1. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children · Alexander Edward Dela Cruz Drilon · 2018 · 2832 citations · Cited by this paper
  2. Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study · 2026 · Related
  3. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials · Robert Charles Doebele · 2019 · 1804 citations · Cited by this paper
  4. Integrated Radioproteomic Modeling for Early Recurrence Prediction and Metabolic Characterization in Hepatocellular Carcinoma · 2026 · Related
  5. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials · David S. Hong · 2020 · 1027 citations · Cited by this paper
  6. Hypoalbuminemia as a Predictive Biomarker of Dyspnea Response to Dexamethasone and Placebo in Patients With Cancer: Secondary Analysis of the ABCD Randomized Clinical Trial · 2026 · Related
  7. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls · James P. Solomon · 2019 · 551 citations · Cited by this paper
  8. Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials · 2026 · Related
  9. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research · C. Marchiò · 2019 · 372 citations · Cited by this paper
  10. Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study · 2026 · Related
  11. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy · Susan Jean Hsiao · 2019 · 232 citations · Cited by this paper
  12. Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I · 2026 · Related
  13. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors · George D. Demetri · 2022 · 222 citations · Cited by this paper
  14. DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers · 2026 · Related
  15. NTRK insights: best practices for pathologists · Jaclyn Frances Hechtman · 2021 · 126 citations · Cited by this paper
  16. Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis · 2026 · Related
  17. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001 · George D. Demetri · 2018 · 66 citations · Cited by this paper
  18. Personalized Molecular Monitoring of a Cryptic DIAPH1::PDGFRB Fusion in Chronic Eosinophilic Leukemia Using Droplet Digital Polymerase Chain Reaction · 2026 · Related
  19. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours · Sophie O’Haire · 2023 · 59 citations · Cited by this paper
  20. Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma · 2026 · Related
  21. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board · Klara Dorman · 2023 · 24 citations · Cited by this paper
  22. Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals · George W. Sledge · 2025 · 22 citations · Cited by this paper
  23. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors · Derrek P. Hibar · 2022 · 21 citations · Cited by this paper
  24. Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non–Small-Cell Lung Cancer · Stephanie Ossowski · 2022 · 15 citations · Cited by this paper
  25. Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions · Mohamed Alaa Gouda · 2024 · 11 citations · Cited by this paper
  26. Safety of current treatment options for NTRK fusion-positive cancers · Adeline T. Yang · 2023 · 10 citations · Cited by this paper
  27. Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis · Ulrik Lassen · 2023 · 9 citations · Cited by this paper
  28. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists · Andrew J. Klink · 2022 · 8 citations · Cited by this paper
  29. Real-World Outcomes of Molecular Tumor Board Treatment Recommendations · Federico Nichetti · 2025 · 7 citations · Cited by this paper
  30. Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study. · Marcia S. Brose · 2024 · 6 citations · Cited by this paper
  31. Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers · Connor Willis · 2024 · 6 citations · Cited by this paper
  32. Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer · Marcia S. Brose · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)